The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 35, No. 11, pp. 1396-1399. DOI 10.1345/aph.10396
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldschmidt, N
Right arrow Articles by Muszkat, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldschmidt, N
Right arrow Articles by Muszkat, M

Research Articles

Compound cardiac toxicity of oral erythromycin and verapamil

N Goldschmidt, T Azaz-Livshits, Gotsman, R Nir-Paz, A Ben-Yehuda, and M Muszkat

OBJECTIVE: To report a case of complete atrioventricular (AV) block and QTc prolongation following coadministration of high-dose verapamil and erythromycin. CASE SUMMARY: A 79-year-old white woman was admitted to the hospital due to extreme fatigue and dizziness. On admission, heart rate was 40 beats/min and blood pressure was 80/40 mm Hg. An electrocardiogram showed complete atrioventricular (AV) block, escape rhythm of 50 beats/min, and QTc prolongation 583 msec. This event was attributed to concomitant treatment with verapamil 480 mg/d and erythromycin 2,000 mg/d, which was prescribed one week before admission. DISCUSSiON: This is the first case published describing complete AV block and prolongation of QTc following coadministration of erythromycin and verapamil. CYP3A4 is the main isoenzyme responsible for metabolism of erythromycin and verapamil. Both drugs are potent inhibitors of CYP3A4 and of P-glycoprotein; this may be the basis for the pharmacokinetic interaction between erythromycin and verapamil. In addition to being a woman, our patient had other risk factors for QT prolongation: slow baseline heart rate (probably induced by verapamil), left-ventricular hypertrophy, and possibly ischemic heart disease. CONCLUSIONS: This life-threatening arrhythmia was probably the result of a pharmacokinetic and/or pharmacodynamic interaction of high-dose verapamil and erythromycin.


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
L. Couture, J. A. Nash, and J. Turgeon
The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart.
Pharmacol. Rev., June 1, 2006; 58(2): 244 - 258.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Geronimo-Pardo, A. B Cuartero-del-Pozo, J. M Jimenez-Vizuete, M. Cortinas-Saez, and R. Peyro-Garcia
Clarithromycin-Nifedipine Interaction as Possible Cause of Vasodilatory Shock
Ann. Pharmacother., March 1, 2005; 39(3): 538 - 542.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. A. Ray, K. T. Murray, S. Meredith, S. S. Narasimhulu, K. Hall, and C. M. Stein
Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes
N. Engl. J. Med., September 9, 2004; 351(11): 1089 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Seral, J.-M. Michot, H. Chanteux, M.-P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke
Influence of P-Glycoprotein Inhibitors on Accumulation of Macrolides in J774 Murine Macrophages
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1047 - 1051.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.